Simone Anna Mader, PhD

Dr. Simone Mader completed her PhD at the Medical University of Innsbruck, Austria in the Department of Neurology. For her PhD studies she has been working on autoantibodies in Multiple sclerosis and Neuromyelitis optica (NMO). Her work focused on anti-aquaporin-4 autoantibodies and their relevance for disease pathogenesis in NMO spectrum disorders.

Dr. Simone Mader is currently working as a postdoctoral fellow in the lab of Dr. Betty Diamond studying anti-brain antibodies in lupus and NMO. She is an S.L.E. Foundation fellow.

Since joining Dr Betty Diamond’s group at The Feinstein Institute for Medical Research, Simone Mader’s research has focused on brain reactive autoanitbodies in neuropsychiatric lupus patients and neuromyelitis optica.

Leopold-Franzens University, Innsbruck, Austria
Degree: BS
2005
Field of Study: Biology

Leopold-Franzens University, Innsbruck, Austria
Degree: Mag.Biol
2006
Field of Study: Master program in Molecular Biology

Innsbruck Medical University, Austria
Degree: PhD
2011
Field of Study: Neuroimmunology

2013 Basic Science Fellowship Grant, S.L.E. Foundation, Inc., 2013-2015
2013 FOCIS Travel Award, Boston
2012 Ursula & Fritz Melchers Award for the PhD thesis and PhD Award of the Austrian Society of Allergology and Immunology (ÖGAI)
2011 Poster Prize at the XI Neuroscience Wintermeeting, Kitzbühel, Austria
2010 Poster Prize at the 8th Annual Meeting of the Austrian Neurological Society (ÖGN), Linz, Austria
2009 Poster Prize at the Neuroscience Day, Innsbruck, Austria

1. Diamond B, Honig G, Mader S, Brimberg L, and T. Volpe B. “Brain-Reactive Antibodies and Disease.” Annual Review of Immunology Vol. 31, 2013 Mar 21;31:345-85.
2. Kitic M, Hochmeister S, Wimmer I, Bauer J, Misu T, Mader S, Reindl M, Fujihara K, Lassmann H, Bradl M; “Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats.” Acta Neuropathologica Communications. 2013.
3. Rostásy K, Mader S, Hennes E, Schanda K, Gredler V, Guenther A, Blaschek A, Korenke C, Pritsch M, Pohl D, Maier O, Kuchukhidze G, Brunner-Krainz M, Berger T, Reindl M. “Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.” Mult Scler. 2012 Jun;69(6):752-6.
4. Gredler V*, Mader S*, Schanda K, Hegen H, Di Pauli F, Kuenz B, Deisenhammer F, Berger T, Reindl M, Lutterotti A; “Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.” Journal Neurol Science. 2013 May, 15;328(1-2):77-82. * These authors contributed equally to the manuscript.
5. Rostasy K, Mader S, Di Pauli F, Huppke P, Gärtner J, Marquart F, Karenfurt M, Tibussek D, Blaschek A, Kornek B, Leitz S, Berger T, Reindl M. “Anti-MOG-IgG antibodies in pediatric patients with optic neuritis.” Archives of Neurology. Arch Neurol. 2012;69(6):752-756.
6. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch M K, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M; “Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.” Journal of Neuroinflammation. 2011 Dec | 8:184.
7. Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, Franciotta D, Rommer P, Mader S, Reindl M, Kleiter I, Ruprecht K, Kristoferitsch W, Melms A, Wandinger K, Wildemann B. “Frequency and syndrome speci”city of antibodies to aquaporin-4 in neurological patients with rheumatic diseases.” Multiple Sclerosis Journal. 2011 Sep | 17(9):1067-73.
8. Pohl M, Fischer M, Mader S, Schanda K, Kitic M, Sharma R, MisuT, Fujihara K, Reindl M, Lassmann H & Bradl M. “Pathogenic T cell responses against aquaporin 4.” Acta Neuropathologica. 2011 Jul | 122(1):21-34.
9. Dujmovic I*, Mader S*, Schanda K, Deisenhammer F, Stojsavljevic N, Kostic V, Berger T, Drulovic J, Reindl M. “Temporal dynamics of cerebrospinal fluid anti aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders.” Journal of Neuroimmunology. 2011 May | 234(1-2):124-30. * These authors contributed equally to the manuscript.
10. Di Pauli F*, Mader S*, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R, Deisenhammer F, Reindl M, Berger T. “Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.” Clinical Immunology. 2011 Mar | 138(3):247-54. * These authors contributed equally to the manuscript.
11. Mader S, Lutterotti A, Di Pauli F, Kuenz B, Schanda K, Aboul-Enein F, Khalil M, Storch MK, Jarius S, Kristoferitsch W, Berger T, Reindl M. “Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica.” PLoS One. 2010 May | 5(5):e10455.
12. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, Lassmann H. “Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.” Annals of Neurology. 2009 Nov | 66(5):630-43.

View more at PubMed